Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi
therapeutics company, today announced that it will report financial
results for the second quarter ending June 30, 2009 on Thursday, August
6, 2009, after the U.S. financial markets close.
Management will provide an update on the company, discuss second quarter
2009 results, and discuss expectations for the future via conference
call on August 6, 2009 at 4:30 p.m. ET. To access the call, please dial
800-599-9816 (domestic) or 617-847-8705 (international) five minutes
prior to the start time and provide the passcode 36308701. A replay of
the call will be available from 7:30 p.m. ET on August 6, 2009 to August
13, 2009. To access the replay, please dial 888-286-8010 (domestic) or
617-801-6888 (international), and provide the passcode 91948590.
A live audio webcast of the call will also be available on the
“Investors” section of the company’s website, www.alnylam.com.
An archived webcast will be available on the Alnylam website
approximately two hours after the event.
About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company developing novel therapeutics
based on RNA interference, or RNAi. The company is applying its
therapeutic expertise in RNAi to address significant medical needs, many
of which cannot effectively be addressed with small molecules or
antibodies, the current major classes of drugs. Alnylam is leading the
translation of RNAi as a new class of innovative medicines with
peer-reviewed research efforts published in the world’s top scientific
journals including Nature, Nature Medicine, and Cell.
The company is leveraging these capabilities to build a broad pipeline
of RNAi therapeutics; its most advanced program is in Phase II human
clinical trials for the treatment of respiratory syncytial virus (RSV)
infection and is partnered with Cubist and Kyowa Hakko Kirin. In
addition, the company is developing RNAi therapeutics for the treatment
of a wide range of disease areas, including liver cancers,
hypercholesterolemia, Huntington’s disease, and TTR amyloidosis. The
company’s leadership position in fundamental patents, technology, and
know-how relating to RNAi has enabled it to form major alliances with
leading companies including Medtronic, Novartis, Biogen Idec, Roche,
Takeda, Kyowa Hakko Kirin, and Cubist. To reflect its outlook for key
scientific, clinical, and business initiatives, Alnylam established “RNAi
2010” in January 2008 which includes the company’s plan to
significantly expand the scope of delivery solutions for RNAi
therapeutics, have four or more programs in clinical development, and to
form four or more new major business collaborations, all by the end of
2010. Alnylam is a joint owner of Regulus, a company focused on the
discovery, development, and commercialization of microRNA-based
therapeutics. Founded in 2002, Alnylam maintains headquarters in
Cambridge, Massachusetts. For more information, please visit www.alnylam.com.
Alnylam Pharmaceuticals, Inc.
Cynthia Clayton, 617-551-8207
(Investors)
cclayton@alnylam.com
or
Yates
Public Relations
Kathryn Morris, 845-635-9828 (Media)
kathryn@kmorrispr.com
